Onconetix, Inc. (NASDAQ: ONCO) Navigates Reverse Stock Split Amidst Prostate Cancer Diagnostic Progress

• Onconetix, Inc. (NASDAQ: ONCO) recently completed a 1-for-10 reverse stock split, a strategic move to adjust its share price.
• The company is making significant progress with its Proclarix® diagnostic blood test for prostate cancer, supported by new peer-reviewed publications and a U.S. validation study.
• Despite previous stock volatility, Onconetix shares are currently trading at $1.22, reflecting a market capitalization of approximately $1.3 million.

Onconetix, Inc. (NASDAQ: ONCO) is a commercial-stage biotechnology company specializing in advanced medical technology. Through its Swiss subsidiary, Proteomedix AG, the company focuses on developing and marketing innovative diagnostics for prostate cancer. Its main product, Proclarix®, aims to improve the accuracy of cancer detection and reduce unnecessary medical procedures for patients, offering crucial investment insights into the medical diagnostics market.

On May 21, 2026, Onconetix completed a 1-for-10 reverse stock split. This action combines every ten existing shares into one new share, which typically increases the stock's price per share without changing the company's total value. This reverse stock split impact was approved by the company's stockholders at a special meeting on April 30, 2026, a key piece of stock market news for investors.

The split follows recent company updates, including progress on its Proclarix® diagnostic blood test. Before the split, the biotechnology stock showed significant movement. As highlighted by Benzinga, shares once surged 23.65% to $0.38 in after-hours trading, reversing an 18.26% decline from the regular session after Onconetix announced clinical progress and positive clinical trial results.

The company also announced two new peer-reviewed publications and the start of a U.S. validation study for Proclarix®. This advanced diagnostic test is used with PSA levels to better identify clinically significant prostate cancer. In partnership with Labcorp, Proteomedix has initiated the multi-center PRIME study in the United States to further validate its diagnostic technology.

Currently, Onconetix shares trade at $1.22, an increase of 10.91% for the day, reflecting its current stock price and daily stock performance. The stock's 52-week range is between $0.91 and $382.50, with the high reflecting price levels before the reverse split. The company has a market capitalization of approximately $1.3 million, with a daily trading volume of over 1.3 million shares, providing a snapshot of its market capitalization and trading volume.